Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection

(2020) Erik R Dubberke et al.   Open Forum Infectious Diseases

United States Valuation of EQ-5D-5L Health States Using an International Protocol

(2019) A. Simon Pickard et al.   VALUE IN HEALTH

Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States

(2018) Dongmu Zhang et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

(2018) L Clifford McDonald et al.   CLINICAL INFECTIOUS DISEASES

Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting

(2018) Simon W. Lam et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness

(2018) Oliver A Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial

(2018) Benoit Guery et al.   LANCET INFECTIOUS DISEASES

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

(2018) Miguel Salavert et al.   ADVANCES IN THERAPY

Clinical and Economic Burden of Peristomal Skin Complications in Patients With Recent Ostomies

(2017) Charu Taneja et al.   Journal of Wound Ostomy and Continence Nursing

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

(2017) Mark H. Wilcox et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

(2017) Hannah E. Burton et al.   PHARMACOECONOMICS

Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection

(2015) Jason C. Gallagher et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Clostridium difficile Infections

(2015) Melinda M. Soriano et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Is Fidaxomicin Worth the Cost? An Economic Analysis

(2013) Sarah M. Bartsch et al.   CLINICAL INFECTIOUS DISEASES

The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States

(2013) A. Messali et al.   NEURO-ONCOLOGY

Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States

(2013) Paul M. Stranges et al.   VALUE IN HEALTH

Systematic review and meta-analysis of outcomes following emergency surgery forClostridium difficilecolitis

(2012) A. Bhangu et al.   BRITISH JOURNAL OF SURGERY

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE